150 related articles for article (PubMed ID: 35819882)
1. The clinical characteristics and prognosis of patients with primary plasma cell leukemia (pPCL) according to the new IMWG definition criteria.
Yan W; Fan H; Xu J; Liu J; Li L; Du C; Deng S; Sui W; Hao M; Yi S; Zou D; Qiu L; Xu Y; An G
Leuk Lymphoma; 2022 Dec; 63(12):2955-2964. PubMed ID: 35819882
[TBL] [Abstract][Full Text] [Related]
2. Clinical and cytogenetic characteristics of primary and secondary plasma cell leukemia under the new IMWG definition criteria: a retrospective study.
Guan J; Ma J; Chen B
Hematology; 2023 Dec; 28(1):2254556. PubMed ID: 37732631
[TBL] [Abstract][Full Text] [Related]
3. Multiple myeloma patients with low proportion of circulating plasma cells had similar survival with primary plasma cell leukemia patients.
An G; Qin X; Acharya C; Xu Y; Deng S; Shi L; Zang M; Sui W; Yi S; Li Z; Hao M; Feng X; Jin F; Zou D; Qi J; Zhao Y; Tai YT; Wang J; Qiu L
Ann Hematol; 2015 Feb; 94(2):257-64. PubMed ID: 25231928
[TBL] [Abstract][Full Text] [Related]
4. Survival outcomes of patients with primary plasma cell leukemia (pPCL) treated with novel agents.
Mina R; Joseph NS; Kaufman JL; Gupta VA; Heffner LT; Hofmeister CC; Boise LH; Dhodapkar MV; Gleason C; Nooka AK; Lonial S
Cancer; 2019 Feb; 125(3):416-423. PubMed ID: 30332496
[TBL] [Abstract][Full Text] [Related]
5. [The clinical characteristics of patients with primary plasma cell leukemia and the efficacy of novel agents and hematopoietic stem cell transplantation].
Li WJ; Wang FR; Wen L; Chen Y; Chen H; Huang XJ; Lu J
Zhonghua Nei Ke Za Zhi; 2020 Oct; 59(10):801-806. PubMed ID: 32987483
[No Abstract] [Full Text] [Related]
6. A clinical perspective on plasma cell leukemia; current status and future directions.
Tuazon SA; Holmberg LA; Nadeem O; Richardson PG
Blood Cancer J; 2021 Feb; 11(2):23. PubMed ID: 33563906
[TBL] [Abstract][Full Text] [Related]
7. [Effect of Circulating Plasma Cells on the Prognosis of Patients with Multiple Myeloma].
Li F; Gao YJ; Li SS; Xi YY; Yang XW; Su YH
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Dec; 31(6):1771-1779. PubMed ID: 38071059
[TBL] [Abstract][Full Text] [Related]
8. Primary Plasma Cell Leukemia: Identity Card 2016.
Musto P; Simeon V; Todoerti K; Neri A
Curr Treat Options Oncol; 2016 Apr; 17(4):19. PubMed ID: 26995215
[TBL] [Abstract][Full Text] [Related]
9. Clinical Characteristics and Outcomes of Patients With Primary Plasma Cell Leukemia in the Era of Novel Agent Therapy.
Nandakumar B; Kumar SK; Dispenzieri A; Buadi FK; Dingli D; Lacy MQ; Hayman SR; Kapoor P; Leung N; Fonder A; Hobbs M; Hwa YL; Muchtar E; Warsame R; Kourelis TV; Russell S; Lust JA; Lin Y; Siddiqui M; Go RS; Jevremovic D; Kyle RA; Gertz MA; Rajkumar SV; Gonsalves WI
Mayo Clin Proc; 2021 Mar; 96(3):677-687. PubMed ID: 33673918
[TBL] [Abstract][Full Text] [Related]
10. How We Manage Newly Diagnosed Multiple Myeloma With Circulating Tumor Cells.
van de Donk NWCJ
J Clin Oncol; 2023 Mar; 41(7):1342-1349. PubMed ID: 36450104
[No Abstract] [Full Text] [Related]
11. [Advances in the Diagnosis and Therapy of Primary Plasma Cell Leukemia -Review].
Wang H; Li JY; Sun C; Zhou X
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Dec; 25(6):1837-1841. PubMed ID: 29262927
[TBL] [Abstract][Full Text] [Related]
12. Primary plasma cell leukemias displaying t(11;14) have specific genomic, transcriptional, and clinical features.
Cazaubiel T; Leleu X; Perrot A; Manier S; Buisson L; Maheo S; Do Souto Ferreira L; Lannes R; Pavageau L; Hulin C; Marolleau JP; Voillat L; Belhadj K; Divoux M; Slama B; Brechignac S; Macro M; Stoppa AM; Sanhes L; Orsini-Piocelle F; Fontan J; Chretien ML; Demarquette H; Mohty M; Schavgoulidze A; Avet-Loiseau H; Corre J
Blood; 2022 Apr; 139(17):2666-2672. PubMed ID: 35171994
[TBL] [Abstract][Full Text] [Related]
13. An update on biology, diagnosis and treatment of primary plasma cell leukemia.
Musto P; Statuto T; Valvano L; Grieco V; Nozza F; Vona G; Bochicchio GB; La Rocca F; D'Auria F
Expert Rev Hematol; 2019 Apr; 12(4):245-253. PubMed ID: 30905220
[TBL] [Abstract][Full Text] [Related]
14. Primary plasma cell leukemia 2.0: advances in biology and clinical management.
Neri A; Todoerti K; Lionetti M; Simeon V; Barbieri M; Nozza F; Vona G; Pompa A; Baldini L; Musto P
Expert Rev Hematol; 2016 Nov; 9(11):1063-1073. PubMed ID: 27759436
[TBL] [Abstract][Full Text] [Related]
15. How I treat plasma cell leukemia.
van de Donk NW; Lokhorst HM; Anderson KC; Richardson PG
Blood; 2012 Sep; 120(12):2376-89. PubMed ID: 22837533
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic advances in the treatment of primary plasma cell leukemia: a focus on hematopoietic cell transplantation.
Nishihori T; Abu Kar SM; Baz R; Alsina M; Harousseau JL; Kharfan-Dabaja MA
Biol Blood Marrow Transplant; 2013 Aug; 19(8):1144-51. PubMed ID: 23416092
[TBL] [Abstract][Full Text] [Related]
17. Bortezomib, Doxorubicin, Cyclophosphamide, Dexamethasone Induction Followed by Stem Cell Transplantation for Primary Plasma Cell Leukemia: A Prospective Phase II Study of the Intergroupe Francophone du Myélome.
Royer B; Minvielle S; Diouf M; Roussel M; Karlin L; Hulin C; Arnulf B; Macro M; Cailleres S; Brion A; Brechignac S; Belhadj K; Chretien ML; Wetterwald M; Chaleteix C; Tiab M; Leleu X; Frenzel L; Garderet L; Choquet S; Fuzibet JG; Dauriac C; Forneker LM; Benboubker L; Facon T; Moreau P; Avet-Loiseau H; Marolleau JP
J Clin Oncol; 2016 Jun; 34(18):2125-32. PubMed ID: 27114594
[TBL] [Abstract][Full Text] [Related]
18. Primary plasma cell leukemia: report of 17 new cases treated with autologous or allogeneic stem-cell transplantation and review of the literature.
Saccaro S; Fonseca R; Veillon DM; Cotelingam J; Nordberg ML; Bredeson C; Glass J; Munker R
Am J Hematol; 2005 Apr; 78(4):288-94. PubMed ID: 15795922
[TBL] [Abstract][Full Text] [Related]
19. Prognostic Implications of Circulating Plasma Cell Percentage in Multiple Myeloma and Primary Plasma Cell Leukemia Defined by New Criteria.
Jin X; Jiang X; Li H; Shen K; Liu S; Chen M; Yang C; Han B; Zhuang J
Acta Haematol; 2024 Apr; ():1-10. PubMed ID: 38626745
[TBL] [Abstract][Full Text] [Related]
20. Primary plasma cell leukemia in Latin America: demographic, clinical, and prognostic characteristics. A study of GELAMM group.
Peña C; Riva E; Schutz N; Ramírez A; Vásquez J; Del Carpio D; Seehaus C; Ochoa P; Vengoa R; Duarte P; Martínez-Cordero H; Figueredo Y; Ríos RO; Ramírez J; Bove V; Roa M; Russo M; Espinoza M; Rodriguez G; Remaggi G; Enciso ME; Chandía M; Fantl D;
Leuk Lymphoma; 2023 Apr; 64(4):816-821. PubMed ID: 36695519
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
